Matthias Huber

Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe

Walid Habre, Nicola Disma, Katalin Virág et al. · The Lancet Respiratory Medicine · 2017 · 762 citations · Full text

Patient Safety, Pediatrics, Outcomes Research +8

Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

Michael A. C. Kane, Fredric S Brandt, Rod J. Rohrich et al. · Plastic & Reconstructive Surgery · 2009 · 130 citations

Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris

Alexander Nast, I. Kopp, Matthias Augustin et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2007 · 94 citations

Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis

Kirsten Siepmann, Matthias Huber, Nicole Stübiger et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2005 · 88 citations

Translational Medicine, Mycophenolate Mofetil, Immunosuppressive Therapy +4

Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case–Control Surveillance Study

Matthias Huber, Frank Andersohn, Giselle Sarganas et al. · European Journal of Clinical Pharmacology · 2014 · 87 citations

Medicine, Hematology, Pathology +1